SCHEMBL2325155

SCHEMBL2325155

CCOP(=O)(O)CC(=O)c1ccc(F)cc1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.36
MAPT P10636 3/20 0.35
LMNA P02545 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 3/20 0.34
HTT P42858 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MMP1 P03956 1/20 0.34
NPC1 O15118 1/20 0.34
ALPL P05186 1/20 0.34
GAA P10253 1/20 0.34
HPGD P15428 1/20 0.34
RAB9A P51151 1/20 0.34
MAPK14 Q16539 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2324615 0.87 CES2 (0.45) MAPTMEN1KMT2AALDH1A1RAB9A
SCHEMBL2322311 0.86 SMN1; SMN2 (0.44) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL1549681 0.85 KMT2A (0.42) MEN1KMT2ANPC1HPGDRAB9A
SCHEMBL2324778 0.84 CES2 (0.45) TSHRMAPTMEN1KMT2ANPSR1
SCHEMBL2329637 0.83 TDP1 (0.43) TSHRMAPTLMNAMEN1KMT2A
SCHEMBL1550118 0.83 EPHX2 (0.39) LMNAMEN1KMT2AALDH1A1GAA
SCHEMBL2331699 0.81 RAB9A (0.40) LMNAMEN1KMT2ACYP1A2CYP2C19
SCHEMBL2322449 0.81 HTR7 (0.47) MAPTLMNAMEN1KMT2AKDM4E
SCHEMBL2325110 0.80 KCNK3 (0.37) TSHRLMNAMEN1KMT2AALDH1A1
SCHEMBL1549244 0.80 KMT2A (0.48) TSHRMAPTLMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904455-B1 PYRIDAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-17 EP disclosed
US-7678795-B2 Pyridazines as 11b-HSD1 inhibitors HOFFMAN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1904455-A2 PYRIDAZINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2008-04-02 EP disclosed
WO-2007003521-A2 PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-01-11 WO disclosed
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HSD11B1, HSD17B1, HSD17B11 TSHR 1422/4885MAPT 2099/4885LMNA 2625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.